Ultrasound (US) sensitive or sonosensitive doxorubicin-containing liposomes based on 1,2 distearoyl-sn-glycero-3-phosphatidylethanolamine (DSPE) as the main lipid component are reported. A variety of lipid bilayer compositions was studied with respect to in vitro US triggered release of drug as well as serum stability in terms of drug retention, using experimental design. The multivariate data analysis indicated a strong correlation between DSPE content and sonosensitivity, both alone and in interplay with cholesterol. The most optimal formulation showed approximately 70% release of doxorubicin after 6 min of US exposure. This represented a 7-fold increase in release extent when compared to standard pegylated liposomal doxorubicin. The significant enhancement in sonosensitivity of the liposomes shows the potential of engineering liposomal lipid composition for US-mediated drug delivery.
Organism species: Pan-species (General)
CATALOG NO. | PRODUCT NAME | APPLICATIONS | |
Proteins | n/a | Complete Antigen of 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE) | Antigenic Transformation Customized Service Offer |
Antibodies | n/a | Monoclonal Antibody to 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE) | Monoclonal Antibody Customized Service Offer |
n/a | Polyclonal Antibody to 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE) | Polyclonal Antibody Customized Service Offer | |
Assay Kits | n/a | CLIA Kit for 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE) | CLIA Kit Customized Service Offer |
n/a | ELISA Kit for 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine (DSPE) | ELISA Kit Customized Service Offer |